Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Donald K Strickland"'
Autor:
Satwant Lally, Bharathi Vennapusa, Scott J. Dylla, M. Catherine Pietanza, Todd M. Bauer, Sky Watson, Melissa Lynne Johnson, Howard A. Burris, Bonnie S. Glisson, Deepan Mathur, Lauren Averett Byers, Hany Zayed, Charles M. Rudin, David R. Spigel, Francisco Robert, Tae H. Han, Sheila Bheddah, Donald K Strickland, Ramaswamy Govindan, Daniel Morgensztern, Neal Ready, Stanford L. Peng, Noah Theiss
Publikováno v:
The Lancet Oncology. 18:42-51
Summary Background Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a8216db6c1c8093641d3464207a88e
https://doi.org/10.1016/s1470-2045(16)30565-4
https://doi.org/10.1016/s1470-2045(16)30565-4
Autor:
Wendy Burke, Stephen Green, Manish Patel, Patricia LoRusso, Elisabeth Oelmann, Erika Hamilton, Muaiad Kittaneh, Donald K Strickland, Howard A. Burris, Suzanne F. Jones, W Larry Gluck
Publikováno v:
Cancer Research. 75:P6-12
Background: Preclinical data suggest that patients with ER+ Breast Cancer become less sensitive to hormonal therapy by upregulation of the mTOR pathway. BOLERO-2 demonstrated that the combination of an allosteric mTOR inhibitor and an aromatase inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::123a9e494da8429e2e105610950184cf
https://doi.org/10.1158/1538-7445.sabcs14-p6-12-01
https://doi.org/10.1158/1538-7445.sabcs14-p6-12-01
Autor:
Manish R. Patel, Suzanne F. Jones, Jay Yang, Julie Charlton, William B. Donnellan, Ehab Atallah, Philip Overend, Jon Travers, Simon Smith, Giulia Fabbri, J. Elizabeth Pease, Carrie A. Adelman, Alexander MacDonald, Donald K. Strickland, Elizabeth Sainsbury, Gautam Borthakur, Adam S. Asch, Alireza Eghtedar, Jan Cosaert, Anna Korzeniowska
Publikováno v:
Blood. 134:3919-3919
Background: Aurora kinases (AurK) represent potential targets for anticancer therapy in hematological malignancies and solid tumors. AurK B inhibitor AZD1152 (barasertib) showed benefit (35% CR/CRi) in patients (pts) with untreated AML when given as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2deda80d1087955185840c7d2dbe4223
https://doi.org/10.1182/blood-2019-130635
https://doi.org/10.1182/blood-2019-130635
Autor:
Melissa Lynne Johnson, Judy Sing-Zan Wang, Howard A. Burris, Philip Overend, Carrie A. Adelman, Julie Charlton, Donald K Strickland, Elizabeth Janet Pease, Alexander MacDonald, Gargi Patel, Jan Cosaert, Gerald Steven Falchook, Carol Greenlees, Suzanne F. Jones
Publikováno v:
Journal of Clinical Oncology. 37:3098-3098
3098 Background: Aurora kinase B (AURKB) represents a potential target for therapy in solid and hematological malignancies. AURKB inhibitor AZD1152 (barasertib) was previously investigated in solid tumor pts in a phase I setting. AZD2811-nanoparticle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f29e2d12a7753b3ac3f565118e01710
https://doi.org/10.1200/jco.2019.37.15_suppl.3098
https://doi.org/10.1200/jco.2019.37.15_suppl.3098
Autor:
Jayanthi S. Lea, Erika Hamilton, Karen Cadoo, H. A. Burris, Naomi Laing, Denise Uyar, Suzanne F. Jones, Setsuko K. Chambers, Ganesh Mugundu, Sharad A. Ghamande, Donald K Strickland, David R. Spigel, D. Spitz, Panagiotis A. Konstantinopoulos, Gottfried E. Konecny, L.M. Chen, Kathleen N. Moore, Amit M. Oza
Publikováno v:
Annals of Oncology. 28:v352-v353
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::653d0e9c47afc25449f8be20107f70f7
https://doi.org/10.1093/annonc/mdx372.061
https://doi.org/10.1093/annonc/mdx372.061
Autor:
Carrie A. Adelman, Manish R. Patel, Ehab Atallah, J. Elizabeth Pease, Suzanne F. Jones, Julie Charlton, Elena Young, Wolfram Brugger, Philip Overend, Donald K. Strickland, Alexander MacDonald, Jon Travers, Elizabeth Sainsbury, Simon Smith, Adam S. Asch, William B. Donnellan
Publikováno v:
Blood. 132:4064-4064
Background: Aurora kinases represent potential targets for anticancer therapy in solid tumors and hematological malignancies. In a phase I/II study, the aurora B kinase inhibitor AZD1152 (barasertib) showed benefit (35% CR/CRi) in patients (pts) with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9942e181fd1220213c35416b61e8a37d
https://doi.org/10.1182/blood-2018-99-118465
https://doi.org/10.1182/blood-2018-99-118465
Autor:
Elizabeth Janet Pease, Howard A. Burris, Gerald Steven Falchook, Julie Charlton, Judy Sing-Zan Wang, Wolfram Brugger, Melissa Lynne Johnson, Donald K Strickland, Suzanne F. Jones, Alexander MacDonald
Publikováno v:
Journal of Clinical Oncology. 36:2592-2592
2592Background: Aurora kinases represent potential targets for anticancer therapy in solid tumors and hematological malignancies. The aurora B kinase inhibitor AZD1152 (barasertib) has shown benefi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b06517d84ab51dad9fd356ca3bf7be0
https://doi.org/10.1200/jco.2018.36.15_suppl.2592
https://doi.org/10.1200/jco.2018.36.15_suppl.2592
Autor:
Anna Marie Hayden, Andrew Jacobs, William M. Dugan, Astra M. Liepa, Hedy L. Kindler, William J. John, Donald K. Strickland, Howard S. Hochster
Publikováno v:
American Journal of Cancer. 4:185-191
Background:Gemcitabine is the standard chemotherapy for the treatment of advanced pancreatic cancer. The novel multitargeted antifolate pemetrexed (Alimta®) has also demonstrated activity in this disease. These two drugs are synergistic in vitro, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::553bdefebcc52b8f11442a83e60ead52
https://doi.org/10.2165/00024669-200504030-00005
https://doi.org/10.2165/00024669-200504030-00005
Autor:
Bharathi Vennapusa, Sky Watson, M. Catherine Pietanza, Howard A. Burris, Neal Ready, Deepan Mathur, Melissa Lynne Johnson, Ramaswamy Govindan, David R. Spigel, Charles M. Rudin, Bonnie S. Glisson, Noah Theiss, Tae Han, Stanford L. Peng, Todd M. Bauer, Hany Zayed, Lauren Averett Byers, Donald K Strickland, Francisco Robert, Scott J. Dylla, Sheila Bheddah, Daniel Morgensztern
Publikováno v:
Journal of Thoracic Oncology. 12:S260-S261
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27e627ac880ec1dbcf3b4199c5db678e
https://doi.org/10.1016/j.jtho.2016.11.252
https://doi.org/10.1016/j.jtho.2016.11.252
Autor:
Jackie Fleckenstein, Shelly Lensing, Mark Levstik, Donald K. Strickland, Jennifer Pope, Patrick J. Dean, Melissa M. Hudson, Caroline A. Riely, Jeanne Carr, Rene Davila, Sharon. M. Castellino, Sarah Kippenbrock, Shesh N. Rai, Shari Taylor, Randall T. Hayden
Publikováno v:
Blood. 103:2460-2466
Childhood cancer survivors transfused before 1992 are at risk for chronic hepatitis C (HCV) infection. In 1995, St Jude Children's Research Hospital initiated an epidemiologic study of childhood cancer survivors with transfusion-acquired HCV. Of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e24ce700ad8fb822ae17886cb3f2037
https://doi.org/10.1182/blood-2003-07-2565
https://doi.org/10.1182/blood-2003-07-2565